MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ocrelizumab (Ocrevus®) via subcutaneous (SC) delivery on the Pharmaceutical [...]

MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ublituximab (Briumvi®) on the Pharmaceutical Benefits Scheme (PBS) for the [...]

MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) to advocate for the amendment of current Pharmaceutical Benefits Scheme (PBS) listings to allow nurse [...]

MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) in support of the request to include ublituximab (Briumvi®) on the Pharmaceutical Benefits Scheme (PBS) for the [...]

Medication Subsidy (PBAC), Medications and Treatments, Disease Modifying Therapy, DMT, Pharmaceutical Benefits Advisory Committee, PBAC

Medication Subsidy (PBAC), Medications and Treatments, Pharmaceutical Benefits Advisory Committee, PBAC, Vaccine

Medication Subsidy (PBAC), Medications and Treatments, Pharmaceutical Benefits Advisory Committee, PBAC, Vaccine

MS Australia is writing to the Pharmaceutical Benefits Advisory Committee (PBAC) to support the inclusion of Shingrix® on the Pharmaceutical Benefits Scheme (PBS) for people with multiple [...]

Medication Subsidy (PBAC), Medications and Treatments, Disease Modifying Therapy, DMT, Pharmaceutical Benefits Advisory Committee, PBAC

Medication Subsidy (PBAC), Medications and Treatments, Disease Modifying Therapy, DMT, Pharmaceutical Benefits Advisory Committee, PBAC